TF and acute myeloid leukemia: Patient MDS2 demonstrated aberrant high activity of the regulon guided by ATF3, which has been shown to drive cell cycle progression in AML, and of that of HOXA6, a TF which potentiates hematopoietic cell differentiation and self-renewal.